Breaking News, Financial News

Financial Report: Emergent BioSolutions

Anthrax vaccines revenue was $103.6 million in the quarter, up 88% largely driven by deliveries to the U.S. government's Strategic National Stockpile.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Financial Report: Emergent BioSolutions  1Q Revenues: $307.5 million (-10%) 1Q Loss: $3.7 million (earnings of $69.7 million 1Q21) Comments: Anthrax vaccines revenue was $103.6 million in the quarter, up 88% largely driven by timing of deliveries to the U.S. government, specifically the Strategic National Stockpile. The company received an AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted) contract modification in September 2021 valued at approximately $399 million to deliver additional AV7909 dos...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters